(NP (-LRB- -LCB-) (NP (DT The) (NN value)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NN test)) (PP (IN of) (NP (NP (NN glucocorticoid) (NNS receptors)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease))))))))))) (-RRB- -RCB-))
(S (SBAR (IN In) (NN order) (TO to) (S (NP-SBJ (-NONE- *)) (VP (VB inquire) (PP (IN into) (NP (NP (DT the) (JJ functional) (NN state)) (PP (IN of) (NP (NP (JJ adrenal) (NN cortex)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (NN heart) (NN disease)))))))))))) (, ,) (S-COOD (S (NP-SBJ-27 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease)))))))))) (VP (VBD was) (VP (VBN determined) (NP (-NONE- *-27)) (PP (IN with) (NP (JJ radioligand-binding) (NN assay)))))) (CC and) (S (NP-SBJ-28 (DT the) (JJ corresponding) (NN plasma) (NN cortisol) (NNS levels)) (VP (VBD were) (VP (VBN assessed) (NP (-NONE- *-28)) (PP (IN with) (NP (JJ radioimmune) (NNS assays))))))) (. .))
(S (NP-SBJ (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S-COOD (S (NP-SBJ-29 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced) (NP (-NONE- *-29)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))))) (CC and) (S (NP-SBJ-30 (PRP it)) (VP (VBD was) (VP (VBN increased) (NP (-NONE- *-30)) (SBAR-TMP (WHADVP-31 (WRB when)) (S (NP-SBJ-32 (PRP$ their) (NN health) (NN state)) (VP (VBD was) (VP (VBN improved) (NP (-NONE- *-32)) (ADVP (-NONE- *T*-31)))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (ADVP (RB still)) (ADJP-PRD (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ-33 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB greatly)) (VP (VBN increased) (NP (-NONE- *-33)) (SBAR-TMP (WHADVP-34 (WRB when)) (S (NP-SBJ-35 (DT these) (NNS patients)) (VP (VBD were) (VP (VBN treated) (NP (-NONE- *-35)) (PP (IN with) (NP (NN oxygen))) (ADVP (-NONE- *T*-34)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ-36 (NP (DT No) (NN difference)) (PP (IN in) (NP (NN plasma) (NN cortisol)))) (VP (VBD was) (VP (VBN found) (NP (-NONE- *-36)) (PP (IN between) (NP-COOD (NP (DT the) (NNS patients)) (CC and) (NP (DT the) (JJ healthy) (NNS subjects)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &gt;) (CD 0.05)))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S-COOD (S (NP-SBJ-37 (NP (DT the) (NN function)) (PP (IN of) (NP (JJ adrenal) (NN cortex)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (NP (-NONE- *-37)) (PP (IN by) (NP-LGS (NP (DT the) (NN compensation) (NN mechanism)) (PP (IN of) (NP (DT the) (NNS patients))))))))) (, ,) (CC but) (S (NP-SBJ (DT the) (JJR lower) (NN GCR) (NN number)) (VP (VBD was) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (NP (NN lacking)) (PP (IN of) (NP (NN oxygen))) (PP (IN in) (NP (DT the) (NNS patients))))))))))) (. .))
(S (NP-SBJ-38 (NP (DT The) (NN number)) (PP (IN of) (NP (NN GCR)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (NP (-NONE- *-38)) (PP (IN by) (NP-LGS (NP (NN inhalation)) (PP (IN of) (NP (NN oxygen)))))))) (. .))
(S (ADVP (RB Therefore)) (NP-SBJ (NN oxygen) (NN therapy)) (VP (VBZ is) (ADJP-PRD (JJ helpful)) (PP (IN in) (S (NP-SBJ (-NONE- *)) (VP-COOD (VP (VBG raising) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors))))) (CC and) (VP (VBG controlling) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (NN disease))))))))) (. .))
